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Therapeutic hypothermia (TH) is standard treatment for neonates (≥36 weeks) with
perinatal asphyxia (PA) and hypoxic–ischemic encephalopathy. TH reduces mortality
and neurodevelopmental disability due to reduced metabolic rate and decreased neuronal
apoptosis. Since both hypothermia and PA influence physiology, they are expected to
alter pharmacokinetics (PK). Tools for personalized dosing in this setting are lacking. A
neonatal hypothermia physiology-based PK (PBPK) framework would enable precision
dosing in the clinic. In this literature review, the stepwise approach, benefits and
challenges to develop such a PBPK framework are covered. It hereby contributes to
explore the impact of non-maturational PK covariates. First, the current evidence as well
as knowledge gaps on the impact of PA and TH on drug absorption, distribution,
metabolism and excretion in neonates is summarized. While reduced renal drug
elimination is well-documented in neonates with PA undergoing hypothermia,
knowledge of the impact on drug metabolism is limited. Second, a multidisciplinary
approach to develop a neonatal hypothermia PBPK framework is presented. Insights on
the effect of hypothermia on hepatic drug elimination can partly be generated from in vitro
(human/animal) profiling of hepatic drug metabolizing enzymes and transporters. Also,
endogenous biomarkers may be evaluated as surrogate for metabolic activity. To
distinguish the impact of PA versus hypothermia on drug metabolism, in vivo neonatal
animal data are needed. The conventional pig is a well-established model for PA and the
neonatal Göttingen minipig should be further explored for PA under hypothermia
conditions, as it is the most commonly used pig strain in nonclinical drug development.
Finally, a strategy is proposed for establishing and fine-tuning compound-specific PBPK
models for this application. Besides improvement of clinical exposure predictions of drugs
used during hypothermia, the developed PBPK models can be applied in drug
development. Add-on pharmacotherapies to further improve outcome in neonatesin.org May 2020 | Volume 11 | Article 5871
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Furthermore, the hypothermia PBPK framework can be used to develop temperature-
driven PBPKmodels for other populations or indications. The applicability of the proposed
workflow and the challenges in the development of the PBPK framework are illustrated for
midazolam as model drug.Keywords: physiology-based pharmacokinetic modelling, neonate, pharmacokinetics, drug metabolism,
therapeutic hypothermiaINTRODUCTION
Perinatal Asphyxia
Despite advances in perinatal medicine, the incidence of
perinatal asphyxia (PA, a clinical condition comprising
perinatal hypoxia, hypercarbia and combined metabolic and
respiratory acidosis) has not decreased in the last decade
(Albrecht et al., 2019). PA occurs in 5.4/1,000 live born
neonates, with 1.8/1,000 live births diagnosed with hypoxic–
ischemic encephalopathy (HIE) (Pokorna et al., 2015). Hypoxic–
ischemic injury to the brain may result in persistent neurological
impairment. This brain injury is secondary to the hypoxic–
ischemic event as well as the reoxygenation–reperfusion after
resuscitation (oxidative stress with production of free radicals)
(Solevag et al., 2019). Besides the immediate cell death (necrosis),
delayed death (apoptosis) of neuronal cells can occur after a
hypoxic insult. This apoptosis process substantially contributes
to the permanent brain damage after PA (Solevag et al., 2019).
Cerebral palsy, epilepsy, mental retardation, cerebral visual
impairment, learning, and behavioral problems can occur as
long term consequences (Albrecht et al., 2019).
Intensive care unit admission with multiple drug treatment is
often needed in neonates presenting PA. Whole body cooling
therapy, also known as therapeutic hypothermia (TH), is used as
standard of care in neonates with PA and HIE since 2010 (NICE,
2010). Criteria to start this treatment slightly differ between
studies. In Figure 1, criteria as used in the TOBY trial are visually
presented (Azzopardi et al., 2008). Therapeutic hypothermia (i.e.
core body temperature of 33.5°C for 72 h) reduces mortality and
neurodevelopmental disability (number needed to treat equal to
7) in term and late preterm neonates with moderate-to-severe
HIE, when initiated before 6 h of age. These 6 h constitute the
therapeutic window to reduce delayed brain damage (Azzopardi
et al., 2009; Jacobs et al., 2013; Azzopardi et al., 2014; Albrecht
et al., 2019). The benefits of hypothermia on survival and
neurodevelopment outweigh the short-term adverse effects.
These benefits are due to reduced metabolic rate and decreased
neuronal apoptosis. Since both TH and PA influence physiology,
they are also expected to alter pharmacokinetic (PK,
concen t ra t ion– t ime) and pharmacodynamic (PD,
concentration–effect) processes.
Neonatal Pharmacology: Driven by
Maturational and Nonmaturational Factors
For each of the four main PK processes, i.e. drug Absorption,
Distribution, Metabolism, and Excretion (ADME), remarkablein.org 2qualitative and quantitative differences have been described
between neonates and adults or between neonates and other
pediatric age groups (Van Den Anker et al., 2018). After oral
ingestion, a drug will be absorbed from the gastro-intestinal tract
(mainly small intestine) and appears in the blood compartment.
The absorption profile will differ in case other routes of
administration are used (e.g. intramuscular, transdermal)
(Kearns et al., 2003). When the intravenous (iv) route is used
for drug administration, the drug appears entirely and directly in
the blood. From the blood compartment, drugs will be
distributed to other organs and tissues. Most drugs are
metabolized to inactive metabolites, which are excreted from the
body. While metabolic clearance is mainly hepatic, elimination
clearance is predominantly renal. The neonatal population is
characterized by prominent changes in growth and maturation,
impacting these ADME processes (developmental pharmacology)
(Smits et al., 2013).
The knowledge on maturational covariates that impact
neonatal drug disposition has substantially increased in the last
decades. Drug absorption after oral ingestion depends on
maturational changes in e.g. gastric pH, gastric emptying,
intestinal transit time and absorption rate. Based on clinical
literature data of selected compounds after iv and oral dosing,
Somani et al. performed a population PK analysis to evaluate
changes in oral drug absorption postnatally. They concluded that
the maturational changes in oral drug absorption occur within
the first week after birth and are drug-independent (Somani
et al., 2016). Besides drug administration by oral route, also
nonenteral routes might be used. Absorption after intramuscular
(im) administration is difficult to predict in neonates due to
reduced skeletal muscle blood flow, and inefficient muscular
contractions on the one hand, and the presence of a higher
capillary density in skeletal muscles in this patient population on
the other hand (Carry et al., 1986; Tayman et al., 2011). For
transdermal absorption, developmental changes in skin
physiology (e.g. thinner stratum corneum in preterms) need to
be taken into account (Allegaert et al., 2017a). Sublingual and
rectal routes for drug administration have the advantage of
bypassing the first-pass effect, but are only rarely used in
neonates. For rectal administration, the extensive exposure
variability in neonates is a major disadvantage. Age-dependent
alterations in body composition and protein binding during early
life, affect drug distribution, while systemic drug metabolism
changes due to maturation of e.g. transporters, liver enzymes as
well as plasma protein binding (Allegaert et al., 2017b). For the
cytochrome P450 (CYP) enzymes involved in phase 1May 2020 | Volume 11 | Article 587
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activity ontogeny profile. At birth, CYP3A7 is the most abundant
CYP iso-enzyme, but during the first year of live CYP3A7 activity
decreases while CYP3A4, the major iso-enzyme for drug
metabolism in adults, displays increased activity during early
life (De Wildt et al., 1999; Ince et al., 2013). This maturation of
CYP, but also glucuronidation capacity in neonates, depends on
both postnatal (PNA) and postmenstrual age (PMA) (Allegaert
et al., 2009). This has been documented for different compounds,
including propofol (Allegaert et al., 2007; Smits et al., 2013).
Besides metabolic elimination, also renal elimination
(glomerular filtration and tubular functions) undergoes
maturation. Ontogeny of glomerular and tubular functions is
driven by age (gestational age, GA and PNA), and PNA also
determines hemodynamic alterations in cardiac output and
regional perfusion. Glomerular filtration rate (GFR) hereby
increases rapidly during the first 2 weeks PNA and reaches
adult capacity at the age of 8–12 months (Kearns et al., 2003;
Rhodin et al., 2009). The above-mentioned developmental
processes illustrate that neonatal physiology directs neonatal
pharmacology and in part accounts for the large inter- and
intraindividual variability in neonatal PK/PD (Smits et al., 2013).
Besides maturational covariates like age, weight or ontogeny
of ADME-relevant proteins, variability in drug disposition also
depends on nonmaturational covariates. Particularly,
environmental factors (e.g. nutrition), genetic polymorphisms,
treatment modalities [e.g. extra-corporeal membrane
oxygenation (ECMO), TH, drug–drug interactions], and
diseases (e.g. asphyxia, sepsis, meningitis) need to be
considered (Allegaert et al., 2017a; Allegaert et al., 2017b).
ECMO is a life-saving therapy for well-selected critically ill
neonates. As recently summarized by Raffaeli et al., the ECMO
modality itself can, in addition to the severe disease conditions
for which ECMO is indicated, increase the volume of distribution
(Vd) for lipophilic, and to a lesser extent, also hydrophilicFrontiers in Pharmacology | www.frontiersin.org 3compounds in neonates. Increased Vd as well as clearance
(CL) during ECMO therefore requires adequate adaptations of
both loading and maintenance doses to keep drug exposure
within therapeutic ranges (Raffaeli et al., 2019). Another example
of nonmaturational factors for drug disposition is disease
condition. As part of the NeoMero trials in neonates with late
onset sepsis (NeoMero-1) and/or meningitis (NeoMero-2),
Germovsek et al. reported a (model-based) penetration of
meropenem, a broad-spectrum carbapenem, into the
cerebrospinal fluid (CSF) of 8% in neonates (Germovsek et al.,
2018). This overall low value was attributed to the absence of
meningeal inflammation in many of the NeoMero-1 patients
without meningitis. However, this percentage rose with
increasing CSF protein, with even 40% penetration predicted at
a protein concentration of 6 g/L, i.e. when inflammation of the
meninges is present (Germovsek et al., 2018). For asphyxiated
neonates treated with TH, both the underlying pathophysiology
as well as the hypothermia treatment are considered as
nonmaturational factors impacting drug disposition. Besides PK,
also PD can be altered during hypothermia. To illustrate this, a
prospective study in neonates receiving TH and treated with
phenobarbital for seizures, no (clinically relevant) effect of TH on
phenobarbital PK was seen, and observed responsiveness was 66%.
In addition, a reduced transition rate from continuous normal
voltage (CNV) to discontinuous normal voltage background
pattern on amplitude integrated electroencephalography was
observed, attributed to the add-on neuroprotection of
phenobarbital in case of CNV pattern (Van Den Broek et al., 2012).
Unfortunately, optimal dosing recommendations for most
conditions in this neonatal subpopulation are often not available.
Tools to support prediction of personalized dosing in the setting
of PA in need for TH, might bridge this gap. (Roka et al., 2007;
Tortorici et al., 2007; Van Den Broek et al., 2010). In this review,
an overview will be provided of the current knowledge on the
impact of hypothermia on the ADME processes, as well asFIGURE 1 | Visual presentation of the sequential evaluation of the criteria used in the TOBY study to determine if therapeutic hypothermia needs to be started in
neonates (Azzopardi et al., 2008).May 2020 | Volume 11 | Article 587
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develop a framework towards precision dosing in the very
specific setting of neonatal PA with TH will be described, as
well as challenges and applicability of this proposal.HYPOTHERMIA AND NEONATAL
DRUG DISPOSITION
Currently Available PK Studies in
Neonates Undergoing
Therapeutic Hypothermia
In order to provide an overview of the currently available
published PK data of individual compounds in neonates
undergoing whole body hypothermia (WBH), a structured
search was performed on PubMed on 21 August 2019 with
‘pharmacokinetics' and ‘hypothermia' as search terms. When
‘newborn' was added, this resulted in 82 hits. Titles and—when
appropriate—abstracts and full papers were assessed with the
intention to illustrate the diversity of compounds with PK data in
this specific subcategory of neonates (Table 1). The bulk of
currently available data relates to antibiotics (n = 5, gentamicin,
amikacin, ampicillin, amoxicill in, benzyl-penicill in),
antiepileptic or potential neuro-protective drugs (n = 8,
phenobarbital, topiramate, erythropoietin or darbepoetin,
midazolam, melatonin, bumetanide, lidocaine), or morphine,
reflecting the currently most commonly used drugs in these
patients. The majority of these compounds are administered by
iv route (n = 12), while two drugs are administered by enteral
route (melatonin, topiramate).
Knowledge on the Impact of Hypothermia
on ADME Processes in Neonates
Neonatal pharmacology and its inter- and intraindividual
variability are driven by maturational physiology and is further
affected by nonmaturational, pathophysiological changes
including asphyxia, and interventions like TH (Allegaert et al.,
2017b). The phenotypic PK hereby reflects the impact of the
(patho)physiology of the individual newborn (renal, hepatic,
and/or circulatory dysfunction), as well as the impact of TH
(reduced energy needs) (Zeilmaker et al., 2018). This setting is
not unique, since similar to e.g. patent ductus arteriosus, where
both the (patho)physiology of the clinical syndrome (vascular
steal phenomenon, with lung overflow, and systemic
hypoperfus ion) (Hundscheid et a l . , 2019) and i ts
pharmacological management (ibuprofen, indomethacin or
paracetamol) will affect the phenotype (Allegaert et al., 2013;
Cristea et al., 2019).
However, the impact of PA and TH on the PK has not a
single, uniform pattern, but will also depend on drug (Log P,
molecular weight, protein binding), individual patient (weight,
extent of renal or hepatic impairment) and ADME (e.g.
extraction ratio) characteristics (Pokorna et al., 2015;
Zeilmaker et al., 2018). This is also reflected in Table 1, in
which a lower gentamicin (Choi et al., 2018) or amikacin (CristeaFrontiers in Pharmacology | www.frontiersin.org 4et al., 2017) clearance is related to TH and/or PA (−31%,
−40.6%), with an increase in clearance (+29%) over time (after
TH, highly correlated with increasing PNA) (Bijleveld et al.,
2016), and weight and/or creatinine as covariates (Frymoyer
et al., 2013; Cristea et al., 2017). A similar pattern can be
observed for different b-lactam antibiotics (ampicillin,
amoxicillin, benzyl-penicillin) with reduced clearance during
controlled hypothermia (−66%) (Cies et al., 2017) and a
subsequent increase in clearance (+58%) over time (Bijleveld
et al., 2018). In contrast, phenobarbital clearance is either similar
(Shellhaas et al., 2013) or only marginally (Pokorna et al., 2019)
decreased and more affected (−55%) by disease severity (Pokorna
et al., 2019). Topiramate data suggest an impact of temperature
(deep versus mild hypothermia, half-life +38% in deep
hypothermia) and time (clearance +21% after rewarming)
(Filippi et al., 2009; Marques et al., 2019). 1-hydroxy-
midazolam elimination clearance is decreased (−26%) during
hypothermia (Favie et al., 2019), while midazolam clearance in
neonates is not influenced by TH but affected by phenobarbital
coadministration (Favie et al., 2019) and renal or hepatic
impairment (Welzing et al., 2013). At least for the TH aspect,
this is similar to findings on the absence of an effect of moderate
hypothermia on midazolam clearance in adults after
resuscitation (Bastiaans et al., 2013). Lidocaine clearance is
decreased (−22%) when compared to a nonasphyxia,
noncooled cohort of term neonates (Van Den Broek et al.,
2013). Morphine clearance is affected when compared to
noncooled asphyxia cases (−22%) (Roka et al., 2008) or
nonasphyxia term neonates (−40 to −50%) (Frymoyer et al.,
2017). Since the different compounds are eliminated by different
routes, the compound specific observations do reflect the specific
impact of TH and/or PA on the elimination route, or the impact
of these covariates on drug disposition (ADME).
Changes in absorption may affect the subsequent patterns of
distribution, metabolism, and excretion. This is because barriers
(like intestinal mucosa, skin) can block, delay, or limit (first pass
metabolism) drugs during passage. Consequently, TH and PA
likely alter drug absorption, resulting in more variable drug
plasma concentrations after enteral administration during TH.
Data on absorption of drugs in a setting of asphyxia and TH in
neonates are at present limited to topiramate and melatonin
(Filippi et al., 2009; Balduini et al., 2019; Marques et al., 2019).
Other pieces of information relate to data on (patho)
physiological changes, like intestinal permeability or intestinal
blood flow. The lactulose and renal lactulose/L-rhamnose
excretion as markers of maturational intestinal permeability
provide evidence for a higher permeability up to at least day 9
in term neonates following perinatal asphyxia (Beach et al.,
1982). Celiac and mesenteric artery flow remained low during
hypothermia with a significant increase after rewarming (peak
systolic velocity celiac 0.63 to 0.77, + 22%; mesenteric 0.43 to 0.55
m/s. +28%), in line with a simultaneous increase in left
ventricular output (106 to 149 ml/kg/min, +40%) (Sakhuja
et al., 2019). Along the same line, bosentan absorption in
critically ill neonates with pulmonary hypertension is delayed
and steady state concentrations were only achieved fromMay 2020 | Volume 11 | Article 587
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physiological factor that influences drug absorption from an
intramuscular injection site is the blood flow in the muscle mass.
This may also be compromised in newborns with poor
peripheral perfusion and low-cardiac-output. Thomson et al.
reported on the variability in gentamicin exposure in young
infants with suspected severe sepsis due to unpredictability in the
rate and extent of absorption after intramuscular administration
(Thomson et al., 2003).
Drug distribution also depends on patient- and drug-related
characteristics, which may change during TH and PA. In vitro
studies with a large set of structurally diverse compounds (n = 19,
Log P values between −3 and +8) on the impact of low
temperature on the fraction unbound for human plasma
suggest that hypothermia itself—if any—only marginally affects
protein binding (Ryu et al., 2018). However, the blood pH itself is
affected by hypothermia since carbon dioxide (CO2) partial
pressure will be lower, and pH is higher during hypothermia,
while the clinical indication for TH usually is associated with
initial metabolic acidosis and pCO2 retention (Van Den Broek
et al., 2010; Pokorna et al., 2015). Since hypothermia affectsFrontiers in Pharmacology | www.frontiersin.org 5blood gas parameters, it is important to take this into account
when interpreting clinical as well as research data in this
population (Groenendaal et al., 2009). Besides the blood pH,
patient-related characteristics like general and regional blood
perfusion, plasma protein composition, or body composition
including water sequestration are also different in this
subpopulation. Furthermore, these characteristics in an
individual patient may evolve over time, with e.g. albumin
concentration dependent on the fluid status or HIE severity
(Muniraman et al., 2017) and changes in alfa-1 glycoprotein
(GA, type of delivery, time after surgical or inflammatory event)
(Calder et al., 2012; Anell-Olofsson et al., 2018). As a result, Vd
can decrease, increase, or remain unchanged. The available
observations in human neonates are very limited, but include
e.g. the ampicillin observations (Vd +30%) (Bijleveld et al., 2018).
Third, hypothermia has been reported to alter drug
metabolism. The knowledge on drug metabolism during
hypothermia remains fragmented and mainly relates to
nonclinical studies and observed increased drug and metabolite
plasma concentrations in human patients when routine dosing is
applied. Since the rate of most enzymatic processes is lower atTABLE 1 | Overview on the pharmacokinetics (PK) of drugs in neonates undergoing therapeutic hypothermia (TH), obtained by a structured Pubmed search.
PMID Drug Log P Study related aspects and findings
30300445 gentamicin −3.1 N = 12 WBH neonates, 2.2, SD 0.7 ml/min/kg
29781085 gentamicin −3.1 pooled data, 8 studies in WBH and non-WBH neonates, trough (+35%) higher, clearance (−31%) lower in WBH
neonates.
26763684 gentamicin −3.1 N = 47 WBH neonates during and after cooling, +29% clearance after cooling.
25225917 gentamicin −3.1 N = 41 WBH neonates, external validation of the PIMD 23553582 dosing regimen.
25070069 gentamicin −3.1 N = 15 WBH vs 19 non-WBH asphyxia neonates, elimination half-life 9.57 vs 7.01 h, +36%.
23702622 gentamicin −3.1 N = 29 + 23 WBH neonates, 5 mg/kg.q24 h to 36 h dosing strategy, elevated trough (>2 mg/l) 38 to 4%.
23553582 gentamicin −3.1 N = 29 WBH neonates, clearance 0.111 × (weight/3.3 kg)0.75 × (1/crea, mg.dl)0.566.
23503448 gentamicin −3.1 N = 16 WBH neonates vs 7 non-cooled asphyxia neonates, clearance -25 %, elimination half-life +40 %.
28993332 amikacin −7.4 N = 56 WBH neonates, compared to noncooled, nonasphyxia cases, clearance −40.6%.
28226400 ampicillin 1.35 N = 13 WBH neonates, clearance lower (−66%), volume of distribution higher (+30%) compared to historical data.
28555724 amoxicillin 0.87 N = 125 WBH neonates, during and after cooling, clearance increases after cooling (0.26 to 0.41 l/h, +58%).
29378710 benzyl-penicillin 1.83 N = 41 WBH neonates, clearance 5.33 l/h.70 kg (system information from PIMD 28555724).
29357720 phenobarbital 1.47 N = 26 WBH neonates, clearance is lower (−15%), because disease severity in WBH neonates affects clearance
(−55%).
23254984 phenobarbital 1.47 N = 39 asphyxia neonates, 20/39 underwent WBH, hypothermia was not a significant covariate for clearance.
23018530 phenobarbital 1.47 N = 31 WBH neonates, typical newborn (3.5 kg) 17.2 ml/h, weight as covariate (kg0.81).
21371018 phenobarbital 1.47 N = 19 WBH neonates, half-life 173.9, SD 62.5 h
19744111 topiramate −0.7 N = 13 WBH neonates, (oral), half-life 35.58, SD 19.3 h (deep vs mild hypothermia, 30–33 vs 33–34°C, half-life + 38%)
31336401 topiramate −0.7 N = 52 WBH neonates, (oral), PK during and after cooling (clearance +21% after cooling)
28099423 erythropoetin n.a. N = 47 WBH neonates, pooled from previous studies, clearance 0.0289 l/h, weight0.75 covariate (1.27)
23008465 erythropoetin n.a. N = 24 WBH neonates, nonlinear pharmacokinetics (half-life 7.2–18.7 h, clearance 15.6–7.7 ml/h.kg)
25989868 darbepoetin alfa n.a. N = 16 WBH neonates exposed, clearance 0.0465 l/h
25996892 darbepoetin alfa n.a. N = 30 WBH neonates, different doses (placebo, 2 or 10 μg/kg <12 h and 7 days), linear pharmacokinetics






68 WBH neonates, phenobarbital coexposure increases midazolam clearance (factor 2.3) during cooling
30734962 melatonin n.a. N = 5 WBH neonates, (oral), 0.21, SD 0.07 l/h.
26189501 bumetanide 2.6 N = 13 WBH neonates, 1 noncooled, mean clearance 0.063 l/h, weight1.7 as covariate
23303304 lidocaine 2.44 N = 22 WBH neonates, compared to N = 26 historical noncooled asphyxia neonates, clearance −24%
18381513 morphine 0.89 N = 10 WBH neonates, and N = 6 non-cooled asphyxia neonates, clearance 0.69 vs 0.89 ml/min.kg (−22%)
27225747 morphine 0.89 N = 20 WBH neonates, 0.765 vs 1.42–1.53 l/h in non-asphyxia, noncooled historical neonates (−40 and −50%
respectively)Some of these PK estimates were compared with either noncooling asphyxia cases, nonasphyxia term cases or were compared to PK estimates (paired) after the hypothermia episode.
The PMID number, the drug involved, its Log P value (PubChem), study related aspects and key findings have been listed. We refer the interested reader to the original publications (by
PMID number) for further details. N, number; PK, pharmacokinetics; SD, standard deviation; WBH, whole body hypothermia.May 2020 | Volume 11 | Article 587
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due to higher than anticipated dose-normalized exposure.
Furthermore, due to reduced hepatic blood flow, metabolic
clearance of drugs with a high hepatic extraction ratio
(propofol −25%) is more affected by hypothermia compared to
low clearance drugs (Van Den Broek et al., 2010; Pokorna et al.,
2015). This illustrates that both reduced liver blood flow and
decreased metabolic capacity (i.e. intrinsic CL) have to be
considered during hypothermia. As summarized by Tortorici
et al. using nonclinical data, hypothermia can decrease the
systemic CL of drugs metabolized by cytochrome P(CYP)450,
by 7–22% per °C below 37°C (Tortorici et al., 2007). Along the
same line, mild hypothermia (35.4°C instead of 37°C) altered
midazolam pharmacokinetics (decrease in metabolite formation
clearance, −11.1%/°C) in healthy adult volunteers (Hostler et al.,
2010). In contrast, and reflecting the complex interaction of
disease and intervention, there was no additional effect of
moderate hypothermia on midazolam clearance in adults after
resuscitation (Bastiaans et al., 2013). In neonates, the available
evidence suggests that 1-hydroxy-midazolam elimination
clearance (renal route) is affected (−26%) during hypothermia
(Favie et al., 2019), while midazolam clearance in neonates is
affected by phenobarbital coadministration (Favie et al., 2019),
renal or hepatic impairment (Welzing et al., 2013). Lidocaine
clearance is decreased (−22%) when compared to nonasphyxia,
not cooled term neonates (Van Den Broek et al., 2013), but these
phenotypic observations may also in part depend on plasma
binding proteins (pH, alpha-1 glycoprotein concentration).Frontiers in Pharmacology | www.frontiersin.org 6Phenobarbital clearance is mainly affected by disease severity
(Pokorna et al., 2019). Morphine clearance, in part depending on
phase 2 metabolism (glucuronidation, sulfation) is decreased in
neonates during TH when compared to noncooled asphyxia
cases (−22%) or noncooled historical controls (−40 to −50%)
(Roka et al., 2008; Frymoyer et al., 2017). Interestingly, peak and
mean bilirubin over time are lower in infants with HIE when
compared to controls, irrespective of the use of TH, although this
likely relates to decreased heme-oxygenase activity and not
glucuronidation (Dani et al., 2018).
Finally, hypothermia reduces renal drug excretion. For drugs
eliminated by glomerular filtration rate (GFR) in neonates with
PA and TH, studies consistently showed that elimination is
significantly (−30 up to −40%) reduced, with an increase after
finalization of the TH (> 72h) (Mark et al., 2013; Ting et al., 2015;
Bijleveld et al., 2016; Cristea et al., 2017; Choi et al., 2018). A
similar pattern can be observed for the different b-lactam
antibiotics (ampicillin, amoxicillin, benzyl-penicillin). A
retrospective analysis on gentamicin trough levels in 55
neonates included in the CoolCAP trial (RCT design with
selective head cooling, not whole-body hypothermia) suggests
that the reduced temperature did not affect gentamicin clearance,
but the renal function impairment (creatinine) correlated (r2 =
0.36) with the trough level (Liu et al., 2009). To further illustrate
the combined impact of maturational changes and PA + TH, we
have plotted the amikacin clearance trends in early neonatal life
based on pooling of reported datasets (Figure 2). There is a
maturational trend in clearance, related to birth weight and PNA
(days 1,2,3,4, as reflected by the colors) compared to a subgroup
of term neonates undergoing TH as treatment for PA (Cristea
et al., 2017; Smits et al., 2017). The impact of hypothermia on
renal tubular functions is still unexplored.
Ongoing Drug Development Plans as Add-
On Interventions to Whole Body
Hypothermia to Improve Outcome
While there is robust evidence that TH reduces mortality and
improves the likelihood of normal neurological outcome
following moderate to severe asphyxia in (near)term neonates,
there is still relevant mortality and morbidity. Consequently,
there is a very active research line investigating add-on
interventions as adjuvant to further improve this setting
(Jacobs et al., 2013). Because of the short timelines (< 6 h
PNA) and the fact that the diagnosis is commonly only made
at delivery, recruitment for such studies is demanding, while a
relevant number of products are at present considered.
In an attempt to provide an overview on the currently
ongoing drug development plans and compounds to improve
the outcome after moderate and severe perinatal asphyxia, we
have explored the clinicaltrial.gov website, the databank of the
European Medicine Agency and performed a nonsystematic
search on PubMed (asphyxia, newborn) on adjuvant or
primary interventions. This resulted in a relevant number of
drug development plans and ongoing studies for Argon, Xenon,
VH-N439, cannabidiol, allopurinol, 2-iminobiotin and
melatonin, besides stem cells related interventions (https://FIGURE 2 | Estimates of amikacin clearance (L/h) trends in early neonatal life
based on pooling of reported datasets (dashed lines). There is a maturational
trend in clearance related to birth weight (g) and postnatal age (PNA, days
1,2,3,4, as reflected by the colors) compared to a subgroup of term neonates
undergoing therapeutic hypothermia as treatment for perinatal asphyxia (solid
lines) (Cristea et al., 2017). The arrows indicate the difference in clearance
between both cohorts for the respective PNA. Adapted from De Cock et al.,
antibiotic dosing in pediatric critically ill patients, Chapter in Antibiotic
pharmacokinetic/pharmacodynamic considerations in the critically ill, Springer
Nature Signapore 2018:239–263, with permission from Springer Nature (De
Cock et al., 2018).May 2020 | Volume 11 | Article 587
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search also resulted in these hits, with magnesium sulfate,
topiramate, and N-acetylcysteine as examples of additional
products or interventions (Mcadams and Juul, 2016; Albrecht
et al., 2019; Solevag et al., 2019). Based on the different
biochemical processes occurring during the different stages of
hypoxic–ischemic injury, Solevag et al. divided these (promising)
add-on therapies in targeting the acute injury phase (to limit
necrosis, e.g. allopurinol, melatonin, xenon, argon, magnesium),
the subacute injury phase (to limit apoptosis, e.g. N-
acetylcysteine, 2-iminobiotin, cannabidiol, and doxycycline)
and the repair phase after PA (to improve recovery, e.g.
erythropoietin, mesenchymal stem cells, topiramate, and
memantine) (Solevag et al., 2019). At present, TH is the only
established therapy in the subacute phase of PA related
brain injury.
For the drug development programs of the compounds listed
above, different animal models were used, while early biomarkers
to assess potential efficacy also differ (biochemical biomarkers,
MRI imaging or electrophysiological signals). This setting
impairs drug development programs and very likely will
benefit from a master protocol approach and a multi-
stakeholder platform as has been reported for other pediatric
orphan settings like pediatric oncology (Woodcock and Lavange,
2017; Khan et al., 2019). In addition, an optimal timing, dosing,
and administration route need to be determined for these
neuroprotective compounds, considering the cooling and
rewarming phases that may impact their disposition. To
achieve this, these product development programs will likely
also benefit from an effective pharmacometric framework for this
specific indication in a special subgroup of neonates. Physiology-
based PK (PBPK) modeling is a promising tool for this setting
(Smits et al., 2019).
PBPK Modeling as Tool for
Personalized Medicine
As the combination of maturational and nonmaturational
covariates results in extensive variability in neonatal drug
disposition, safe and effective pharmacotherapy requires proper
investigation of drugs in this vulnerable population and driven
by their unique (patho)physiology. Nevertheless, most drugs are
currently still developed based on adult pathophysiology and
driven by adult indications (Allegaert et al., 2018). In addition,
knowledge on specific neonatal pathophysiological processes and
disease mechanisms is still limited compared to other
populations. These shortcomings urgently highlight the need
for structured and innovative approaches to make progress in the
field of neonatal pharmacology.
A promising tool is PBPK modeling which combines drug-
specific information with available physiological data of the
population of interest. PBPK aims to generate a predictive
model which mathematica l ly descr ibes under ly ing
physiological and biochemical processes explaining ADME of
the studied compound. The species to be modeled is represented
as a set of various compartments, representing organs or tissues,
which are interconnected by the venous and arterial bloodFrontiers in Pharmacology | www.frontiersin.org 7(Khalil and Laer, 2011). In general, drug transfer between the
blood and the various tissue compartments is captured in
equations, taking into account blood flow to the specific
tissues, tissue volumes, the change in drug concentration over
time, and the tissue–plasma partition coefficients (Michelet et al.,
2017). The concept itself has already been introduced years ago
but has been applied to the pediatric population only the last 2
decades. For neonates, knowledge on ontogeny and maturation
of different systems has to be integrated in this approach
(Michelet et al., 2017). In conclusion, since PBPK modeling
allows for capturing the rapidly changing, time-dynamic
physiological maturation of the neonatal period, combined
with the impact of nonmaturational factors, it is considered as
a crucial tool to improve neonatal pharmacotherapy. More
specifically, PBPK facilitates drug dose prediction and
(pediatric) drug development programs, including clinical trial
development and conduct (Khalil and Laer, 2011; Michelet
et al., 2017).
PBPK Modeling to Support Drug Dose Precision and
Drug Development During Hypothermia in Neonates
At present, the predictive performance of neonatal PBPK models
is limited, both for drugs metabolized by CYP enzymes as well as
for renal excreted drugs (Zhou et al., 2016; Zhou et al., 2018).
Knowledge on system ontogeny and on the effect of
nonmaturational covariates on drug disposition is needed to
further improve neonatal PBPK models (Smits et al., 2019).
Therapeutic hypothermia in neonates is one of the conditions for
which development of a PBPKmodel is urgently needed. First, by
considering TH as a nonmaturational covariate, a PBPK model
would enable more individualized drug exposure prediction.
Although TH often is standardized, clinical care and
supportive therapy including antibiotics, antiepileptics,
inotropics and analgo-sedatives in these neonates may differ
between institutions, which can influence outcomes in the setting
of TH. PBPK modeling can be useful in optimizing dosing
guidelines for these supportive therapies. Second, although TH
is effective, further outcome improvement in these patients is
feasible with add-on pharmacotherapy (section Ongoing Drug
Development Plans as Add-on Interventions to Whole Body
Hypothermia to Improve Outcome). Accurate dose prediction
of these promising and neuroprotective add-on compounds
would benefit from a PBPK framework. The strategy to
develop such a framework will be discussed in the next section.
Strategy for PBPK Framework
Development
General, Multidisciplinary, and Translational
Approach
Based on the summary provided in the section Hypothermia and
Neonatal Drug Disposition of this review, the impact of
hypothermia on renal drug elimination in neonates seems
relatively well covered, while knowledge regarding the effect of
hypothermia on drug metabolism is limited and fragmented.
Since pharmacotherapy during hypothermia is mainly
intravenously, the absorption phase is not present and onlyMay 2020 | Volume 11 | Article 587
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new data generation and research in this field should focus on the
impact of hypothermia on drug metabolism. This additional
knowledge is essential in the development of a PBPK modeling
platform that allows for describing and predicting the impact of
TH on drug disposition in asphyxiated neonates. In the current
section, we aim to provide a strategy on how to develop this
PBPK framework, based on nonclinical and clinical data. We will
hereby integrate an approach to generate new data on the main
knowledge gap, i.e. the impact of hypothermia on drug
metabolism. Overall, a multidisciplinary and translational
approach is needed, combining in vitro as well as in vivo
animal and human data. Figure 3 presents the approach, in
which physiological information of the population of interest
(i.e. neonates), including the impact of (non)maturational
covariates (i.e. asphyxia, hypothermia) and compound-specific
information are combined (Figure 3). To assess the impact of
hypothermia on drug metabolism (step 1), controlled
hypothermia can be applied on cryopreserved (neonatal)
hepatocytes from human donors and animals to determine the
impact of temperature on expression and function of drug
metabolizing enzymes (DME) and drug transporters (DT)
(step 1a). Selection of the optimal juvenile animal model is of
utmost importance. As will be discussed more in detail later in
this review (section In Vivo Studies in Animal Models), the
newborn conventional piglet is already a well-established
translational model for neonatal asphyxia due to the natural
occurrence of the condition in this species, but also due to its
large body size at birth which allows for surgical application and
sampling of the animals (Cheung et al., 2011). As the Göttingen
Minipig is the most commonly used pig strain in nonclinical
drug development (Bode et al., 2010; Colleton et al., 2016), this
model could provide very useful data for pediatric drug use and
development. Next, exploration of the utility of endogenous
biomarkers reflecting DME and DT, both in the human in vivoFrontiers in Pharmacology | www.frontiersin.org 8neonatal setting as well as in the minipig, is useful to gain new
data for the PBPK model development (step 1b). Endogenous
biomarkers are considered as surrogate for determinants of
h ep a t i c d rug e l im ina t i on by e . g . CYP3A4 (4b -
hydroxycholesterol, 4b-OHC; 6b-hydroxycortisol, 6b-OHF)
and OATP (organic anion transporting polypeptide)1B1/3
(coproporphyrin I and III, CPI-III). Combining the data on
drug disposition achieved in steps 1a and 1b, with available
literature data on physiology and on in vivo PK observations,
allows for developing the model (step 2). PBPK-based
predictions of dose–exposure relationships for selected model
compounds (selected based on physicochemical/PK
characteristics and clinical relevance) should be the final aim
of this step. Primarily renally cleared compounds versus
primarily hepatic cleared compounds need to be considered as
candidates. Subsequently, available in vivo PK data in neonates
with PA and TH, as well as data collected in an experimental in
vivo setting, i.e. in a neonatal/juvenile animal model (including
the selected model compounds), can be used to evaluate the
model (step 3). Verification of PBPK-based predictions against
clinical data, followed by model optimizations can be used as a
strategy to achieve a robust PBPK framework. This strategy
requires collaboration of (human and veterinary) clinicians,
modelers and basic scientists. The nonclinical steps hereby
allow for distinguishing the impact of asphyxia versus
hypothermia, which is not feasible in the clinical setting. In the
section Endogenous Biomarkers as a Surrogate for CYP3A and
OATP1B1/3 Activity, an overview of current knowledge and
limitations on selected human endogenous biomarkers, of
relevance for further research in TH condition, will be
provided followed by current evidence and challenges on in
vitro (section In Vitro Approaches to Explore the Impact of TH on
PK in Neonates) and animal in vivo (section In Vivo Studies in
Animal Models) research useful for the development of a robust
neonatal PBPK hypothermia framework.FIGURE 3 | Strategy for neonatal hypothermia PBPK framework development. PBPK, physiology-based pharmacokinetics; DME, drug metabolizing enzymes; DT,
drug transporters.May 2020 | Volume 11 | Article 587
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and OATP1B1/3 Activity
Population-specific biomarker values and their covariates are
useful in the development of PBPK models for compounds
undergoing metabolism. The above mentioned biomarkers,
plasma 4b-OHC (and 4b-OHC/cholesterol ratio), urinary 6b-
OHF (and 6b-OHF/cortisol ratio) and, CPI-III will be further
discussed. Table 2 presents biomarker values of healthy (pre)
term neonates as retrieved in English papers of which full text
was accessible. Values assessed in pathologic conditions, as well
as values collected in the same subjects but after the neonatal
period, were excluded. To assess these biomarkers in neonates
with PA and TH, collaboration with multicenter trials, preferably
following a master protocol approach as mentioned in the
section Ongoing Drug Development Plans as Add-On
Interventions to Whole Body Hypothermia to Improve Outcome,
is suggested due to the orphan condition of this disease.
4b-OHC
Is exclusively formed from cholesterol in the liver and gut by
CYP3A4, with only a minor contribution from CYP3A5. 4b-
OHC displays low intraindividual variability (7.1% range 4.8–
13.2% over 3 months, and a −8.2 to 1.7% change from baseline
over a period of 3–30 days in healthy volunteers) and has a longFrontiers in Pharmacology | www.frontiersin.org 9half-life (60 h to 17 days in adults) with CYP7A1, the rate
limiting enzyme in bile acid synthesis, as considered responsible
for the slow elimination of 4b-OHC (Mao et al., 2017).
Therefore, 4b-OHC represents a weighted average of CYP3A
activity over a period of several days (Tomalik-Scharte et al.,
2009). This allows the quantification of baseline CYP3A activity
from a single blood sample. The impacts of genetics, gender, and
to a limited extent, disease as factors contributing to
interindividual variability in 4b-OHC have been investigated in
adults (Mao et al., 2017). Recently, CYP3A activity was observed
to be lower in type 2 diabetic compared to nondiabetic subjects,
and this decrease was reflected in 4beta-OHC concentrations and
4beta-OHC/cholesterol ratio (Gravel et al., 2019). Based on 4b-
OHC plasma concentrations in Swedes, Koreans, and
Tanzanians, Diczfalusy et al. reported interethnic differences in
both CYP3A4 activity and the frequency of active CYP3A5*1
alleles (Diczfalusy et al., 2011). In addition, the authors reported
that women have higher 4b-OHC concentrations compared to
men. Also, in Ethiopians, higher 4b-OHC and 4b-OHC/
cholesterol ratio was documented in women compared to men
(Gebeyehu et al., 2011).
Overall, the relationship between CYP3A activity and 4b-OHC
is complex, and there are different opinions on the role and
validity of 4b-OHC as biomarker. Based on a study in healthyTABLE 2 | Summary of biomarker values (surrogates for CYP3A and OATP1B1/3 activity) of healthy (pre)term neonates as retrieved in English papers of which full text
was accessible.
Biomarker and reference Number of neonates PNA (days) Biomarker valuea Sample
4b-OHC
Nylen et al., 2011 8 1 12 ng/ml (QR 5,4) Cord blood
14 2-3 20.2 ng/ml (QR 4,7) Venous blood
4b-OHC/cholesterol ratio
Nylen et al., 2011 8 1 0.19 (QR 0.07) Cord blood
6b-OHF
Kishida and Fukushima, 1977 6 NA 530 ± 156 ng/ml,
range 313–683 ng/ml
Urine spot sample
Pal, 1980 20 2–7 41±7 μg/24h,
range 30–52 μg/24h
24 h urine collection
Patel et al., 1996 12 (term) 15–90 31.67 ± 6.55 ng/ml 4 h urine sample
6b-OHF/cortisol ratio
Vauezelle-Kervroudan et al., 1996 7 (preterm)
13 (term)
1–15 7.2 ± 3.8 (preterm)
7.9 ± 5.6 (term)
Urine spot sample
Nakamura et al., 1998 42 (preterm)
39 (term)
1 5.3 ± 0.9 (preterm)
16.5 ± 1.9 (term)
Urine spot sample










Wolkoff and Arias, 1974 23 (preterm) NA 11.2 ± 8.4 μg/m²/24 u (CPI)
6.3 ± 5.3 μg/m³/24 h (CPIII)
Random urine samples
Minder and Schneider-Yin, 1996 18 4-10 17.08 (35.68) μmol/mol creatinine (CPI)b
8.65 (22.75) μmol/mol creatinine (CPIII)b
Random urine samples
Ozalla et al., 2002 68 (term) 3 13.7 (6.3–18.7) (CPI)c
10.2 (5.2–20.5) (CPIII)c
Spot urine sample
Kunitata et al., 2016 31 (15 preterm) 0–6 months ≥0.3 in 80% of infants
[CPI / (CPI + CPIII)]
Urine spot sampleMay 2020 | VValues assessed in pathologic conditions as well as values collected in the same subjects but after the neonatal period, were excluded. aValues are expressed in median (range) or mean ±
SD, unless otherwise stated; bvalues expressed as mean (mean+2SD); cvalues expressed as total population median and QR. Population consisted of 38 cases with maternal exposure to
airborne hexachlorobenzene and 30 cases without exposure; QR, quartile range; PNA, postnatal age; NA, not available; 4b-OHC, 4beta-hydroxycholesterol; 6b-OHF, 6beta-
hydroxycortisol.olume 11 | Article 587
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Tomalik-Scharte et al. showed only a weak correlation of 4b-
OHC and midazolam (as prototypic CYP3A substrate) clearance.
The authors concluded that the currently available data do not
justify the use of 4b-OHC as endogenous CYP3A biomarker,
especially not for assessing basal CYP3A activity. Only for changes
in CYP3A activity driven by strong inducers and inhibitors it may
be useful (Tomalik-Scharte et al., 2009). Kasichayanula et al.
reported that changes in 4b-OHC are useful as surrogate for
midazolam PK after multiple doses of a potent CYP3A inducer
(Kasichayanula et al., 2014). However, since the relationships
found between 4b-OHC and midazolam CL in different reports
have statistical limiations, Ma et al. do not believe that 4b-OHC/
cholesterol ratio has been validated as a biomarker for CYP3A
activity (Ma et al., 2013). In addition, reports on poor correlations
with the clearance of CYP3A substrates e.g. midazolam are
available (Neuhoff and Tucker, 2018). To further illustrate this,
currently available clinical data and simulation analyses support
the use of 4b-OHC to assess potential CYP3A inducers in drug
development (Kasichayanula et al., 2014), but the change in 4b-
OHC concentration is often not linear to the change in specific
compound clearance. The same holds true for CYP3A inhibitors,
since no general trend between the responses of 4b-OHC in the
presence of CYP3A inhibitors can be seen. Based on some of the
limitations mentioned above, it was recently questioned if 4b-
OHC would ever be a robust quantitative biomarker of CYP3A4
activity. In addition, after formation of 4b-OHC, it is further
metabolized by CYP7A1 and CYP27A1. The contributions of all
CYP isoforms involved finally determine the 4b-OHC plasma
concentration (Neuhoff and Tucker, 2018). In conclusion,
although this biomarker and its ratio with cholesterol are
considered as promising in adults, further research and
validation studies are needed. Due to its long half-live, 4b-OHC
is not appropriate to evaluate rapid changes in CYP3A activity
(Mao et al., 2017). Exogenous markers like midazolam or quinine
are preferable for short-term studies, while 4b-OHC is amarker of
CYP3A activity in long-term studies, especially to assess
induction, but also inhibition (Diczfalusy et al., 2011). At
present, 4b-OHC is mainly used in research settings. Mao et al.
hereby recommend an investigation of hepatic CYP3A activity in
clinical pharmacology studies using 4b-OHC (Mao et al., 2017). In
addition, these authors state that assessment of the baseline 4b-
OHC concentrations in special populations, e.g. children, is one of
the current knowledge gaps in 4b-OHC.
Observations in neonates are limited. Nylen et al. determined
4b-OHC and 4b-OHC/cholesterol ratio at birth and 4 months
PNA in 21 neonates (Nylen et al., 2011). At birth, neonates had
lower plasma 4b-OHC than their mother as well as healthy
adults. This was attributed to the low cholesterol values in
newborns, which increased fast and even more than doubled in
the first 4 months of life. Neonates had a median ratio (0.19)
comparable to adults already at birth (Nylen et al., 2011). This
ratio did not change during the first 4 months of life. The
different CYP3A activity ontogeny profiles reported based on
4b-OHC or probe compounds (Stevens et al., 2003; Johnson
et al., 2008) may be related to the different substrate specificitiesFrontiers in Pharmacology | www.frontiersin.org 10of CYP3A enzymes. It is also not clear if CYP3A7 (fetal
expression) would actively contribute to 4b-OHC formation.
6b-OHF
Cortisol is metabolized to 6b-hydroxycortisol by CYP3A4,
mainly in the liver and also in the kidney, placenta, and
adrenal glands, and it is excreted in urine. In line with the
findings on 4b-OHC, conflicting evidence can also be found on
the relevance of 6b-OHF as endogenous CYP3A biomarker.
Based on a review of 277 papers, Galteau and Shamsa
conclude that urinary 6b-OHF is a useful parameter to
evaluate enzyme inducing or inhibiting characteristics of drugs
in case the subjects are their own controls, due to the extensive
interindividual variability in cortisol metabolism. They consider
6b-OHF excretion not reliable enough to determine actual
CYP3A4 activity (Galteau and Shamsa, 2003). Interindividual
variability in 6b-OHF is in part attributed to variability in
CYP3A4 expression. Studies investigating the impact of gender
on 6b-OHF concentrations, both in adults and in children, are
contradicting, but mostly not statistically significant (Galteau
and Shamsa, 2003; Eldesoky et al., 2007). Since cortisol itself
displays a diurnal variation, and intraindividual variability in 6b-
OHF concentrations differ across reports, the 6b-OHF/cortisol
ratio is often suggested to be more useful. According to Chen
et al., the intraindividual variability of this ratio is moderate, and,
measured in a single urine sample, this ratio reflects reasonably
well the mean value of the ratio over a period of 2 months (Chen
et al., 2004). In contrast, another group compared total body
clearance of midazolam with the urinary 6b-OHF/cortisol ratio
as markers of CYP3A activity but was unable to demonstrate a
significant correlation (Chen et al., 2006). Although midazolam
and cortisol both are Class 1 BCS compounds, the high intra-
and interindividual variability in the cortisol ratio may mask the
possible correlation between both biomarkers. These authors
therefore consider the ratio as a suboptimal phenotyping tool for
CYP3A (Chen et al., 2006). On the other hand, Shin et al.
reported that the 6b-OHF/cortisol ratio is the best predictor
for hepatic CYP3A activity under both maximal inhibition and
maximal induction and concluded that a predictive model
including this ratio as covariate is useful to predict the impact
of drug interactions mediated by CYP3A (Shin et al., 2016).
In neonates, reports on urinary 6b-OHF concentrations are
highly variable, from high (530 +/− 156 ng/ml) (Kishida and
Fukushima, 1977), to very low values (31.67 +/− 6.55 ng/ml)
(Patel et al., 1996). For 6b-OHF/cortisol ratio, also conflicting
results can be found. Vauzelle-Kervroudan et al. reported higher
ratios in preterm and term neonates (PNA 1–15 days) compared
to older infants (30–359 days) (Vauzelle-Kervroedan et al.,
1996), while others found different or opposite results
(Nakamura et al., 1998). Nakamura et al. found a correlation
between the ratio and GA and also birth weight (Nakamura et al.,
1998). For preterm neonates, the ratio at birth was lower
compared to term cases and remained stable the first 14 days
of life (Nakamura et al., 1998). However, the same group
reported that 6b-OHF/cortisol ratio in term neonates was high
on the day of birth, independent of the CYP3A activity of theirMay 2020 | Volume 11 | Article 587
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these term cases and reached a level equal to preterm cases at
PNA 5 days. Although a full explanation is not yet available,
alterations of CYP3A7 in neonates are suggested as a possible
contributing factor (Nakamura et al., 1999). In young children, a
different evolution of 6b-OHF at PNA day 90 versus 195 was
seen, depending on if and which medication their mother was
taking during breastfeeding (Toddywalla et al., 1995). Overall, in
adults, 6b-OHF/cortisol excretion decreases after the age of 50–
60 years. Results in neonates and children on this trend are
confl icting and need further research (Galteau and
Shamsa, 2003).
CP1 and CPIII
Both in vitro and in vivo studies indicate the suitability of
coproporphyrins (CPs) as endogenous biomarkers for (OATP)
1B-mediated drug–drug interactions. The human (OATP) 1B1
and 1B3 are DT, which are expressed at the sinusoidal membrane
of hepatocytes (Kunze et al., 2018). CPI and CPIII are byproducts
of the heme biosynthesis and are eliminated by hepatobiliary and
renal route. CPI and CPIII are substrates of OATP1B1 and 1B3.
In addition, CP1 is substrate of multidrug resistance-associated
protein (MRP) 2, while CPIII is also defined as a substrate of
OATP2B1 (Kunze et al., 2018). Kunze et al. observed that
changes in plasma concentrations of these markers due to mild
to strong OATP1B inhibitors were predictive for moderate and
strong OATP1B-mediated drug–drug interactions and that CPI
exposure was useful to distinguish between mild and moderate
interactions (Kunze et al., 2018).
In the newborn period, CPI is the predominant fraction of
excreted CPs, i.e. about 68.4 ± 12.3% of total CPs. Subsequently,
CPI concentration and its fraction of total CP decrease in the first
6 months of life and approach the adult values at age 9 years
(Minder and Schneider-Yin, 1996). Excretion of CPI occurs by
biliary-fecal route, in line with bilirubin. This elimination
pathway is still immature in neonates. Minder and Schneider-
Yin suggested that the excess of CPI, although hydrophobic, is
forced into the renal elimination route due to an overloaded
biliary-fecal transport (Minder and Schneider-Yin, 1996). The
predominance of CPI in neonates is also documented for
preterm cases. Based on urinary data, preterms excrete a
significantly higher percentage of total CP as CPI isomer (59.4
± 17.3%) compared to healthy adults (24.6 ± 5.6%). This CPI
excretion (expressed in μg/m²/24 h) was not significantly
different in preterms compared to healthy adults. CPIII urinary
excretion (expressed in μg/m²/24 h) was significantly lower in
preterm neonates compared to healthy adults (Wolkoff and
Arias, 1974). Recently, Kunikata et al. investigated the
developmental pattern of urinary CP[I/(I+III)], as a marker for
the ATP-binding cassette, subfamily C, member 2 (ABCC2)
function. The authors observed that the CP[I/(I+III)] ratio
varies extensively in infants up to 6 months of age.
Furthermore, the ratio is inversely correlated with corrected
GA, and lowest values are achieved at the age of 1–2 years,
suggesting highest ABCC2 activity at that age. In summary,
although the currently available data are promising, additionalFrontiers in Pharmacology | www.frontiersin.org 11research is needed to further unravel the applicability and
selectivity of CPI and CPIII as endogenous biomarkers.In Vitro Approaches to Explore the Impact of TH on
PK in Neonates
As compared to the significant insights regarding the impact of
hypothermia on renal drug elimination (see Table 1),
quantitative knowledge regarding the impact of TH on the
function of DME and DT is much more limited. Nevertheless,
very few in vitro studies have specifically explored the impact of
moderate hypothermia (32–34°C) on the activity of DME. For
instance, cytochrome P450 (CYP)-mediated ethyl-morphine N-
demethylation in pig liver microsomes was about 31% lower at
32 versus 38°C (Fritz et al., 2005). A few more studies have
reported the effects of severe hypothermia (26°C) on drug
metabolism, mostly in model systems prepared from animals
(Van Den Broek et al., 2010). For instance, McAllister et al.
(Mcallister and Tan, 1980) demonstrated that the affinity (=1/
Km) of verapamil and propranolol for DME was decreased
significantly at 26°C compared to 37°C. This observation also
implies significantly reduced metabolizing capacity at
(substantially) reduced temperatures.
Given the predominant role of the liver in metabolic drug
elimination, future in vitro research in this context should focus
on the full exploitation of multiple liver-derived in vitro models
for drug elimination, e.g. primary hepatocytes in different
configurations (suspensions, cultures), microsomes, or
recombinantly expressed cytochrome P450 (CYP) enzymes.
The combined use of multiple in vitro models carries the
possible advantage that intrinsic effects of temperature on
DMET that are also present in extrahepatic locations (e.g. the
intestine) may be derived.
The major advantages of in vitro tools to explore the
temperature dependence of hepatic drug metabolism are: (i)
experimental conditions, in particular temperature, can be
st r ic t ly contro l led ; ( i i ) the temperature e ffect on
biotransformation processes can be evaluated for a sufficiently
broad range and at high resolution (i.e. with high precision); (iii)
the primary underlying mechanisms (e.g. transporters versus
drug metabolizing enzymes) of the possible temperature
dependency can be evaluated; (iv) by selecting the proper in
vitro tools immediate versus delayed effects of temperature can be
evaluated; (v) in view of the significant throughput of in vitro
tools for hepatic drug disposition, multiple compounds can be
studied, enabling to evaluate the genericity versus drug-
specificity of the findings; (vi) the use of pooled hepatocytes
versus hepatocytes from individual donors allows for exploring
the possible intersubject variability of the temperature-
dependent processes. Correlation of donor-specific effects with
donor demographics may also support implementation of
donor-specific factors (i.e. explaining part of the intersubject
variability) to the eventual PBPK framework. Specifically, in the
context of TH in neonates, the influence of temperature on
hepatic drug disposition processes can be studied in hepatocytes
obtained from neonatal versus adult liver tissue donors. At theMay 2020 | Volume 11 | Article 587
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batches of neonatal hepatocytes will also present the challenge of
unknown effects of numerous other covariates.
Specifically, to explore the effect of TH on hepatic drug disposition
proteins, it is important to distinguish between immediate (4–6 h)
and delayed (> 24h) effects of hypothermia. Immediate effects
encompass the influence of temperature on protein stability (i.e.
degradation rate) as well as the effect of temperature on catalytic
protein activity (i.e. intrinsic activity). Delayed effects are considered
the result of the possible influence of temperature on protein
expression. Such effects may include mechanisms of altered
activation of nuclear receptor-mediated pathways, as well as the
possible influence of temperature on transcriptional and
translational activities. Proposed methodological details for
evaluating both immediate and delayed effects of temperature on
hepatic DME and DT have been summarized in Table 3.Frontiers in Pharmacology | www.frontiersin.org 12In Vivo Studies in Animal Models
Much of the current understanding of PA in man has been
derived from animal studies. As pointed out in a review by
Michael Painter, the use of animal models for this condition has
a long history (Painter, 1995). Resistance of the neonate to
asphyxia, in terms of duration of survival, has already been
described in the early days in several animal models that were
submitted to different ways of asphyxial insult (Fazekas et al.,
1941; Glass et al., 1944; Britton and Kline, 1945; Stafford and
Weatherall, 1960). There is a good correlation between maturity
and resistance to asphyxia. Males appear to be less resistant than
females (Britton and Kline, 1945), and high body temperature
also reduces resistance. In neonatal rats for example, it has been
clearly shown that lowering the body temperature from 37 to 30°
C during asphyxia has a protective effect (Saeed et al., 1993).
Altricial species are more resistant to asphyxia than precocialTABLE 3 | Proposed experimental conditions for in vitro evaluation of the immediate versus delayed effects of hypothermia on activity of drug metabolizing enzymes
(DME) and drug transporters (DT).
Immediate effects of hypothermia on in vitro activity of DME and DT
Model systems and selected DME and DT
i. Both pooled human liver microsomes, S9 fractions and suspended human hepatocytes (2 pooled and at least 3 individual neonatal donors) should be used as
model systems to evaluate the impact of hypothermia (33–37°C) on the activity of the most important hepatic DME, including CYP1A2, CYP2B6, CYP2C8/9/
19, CYP2D6, CYP3A4, CYP2E1, Flavin- Containing Monooxygenase (FMO)1-3, uridine 5́ -diphospho-glucuronosyltransferases (UGT's), aldehyde oxidases,
and esterases;
ii. Suspended human hepatocytes (pooled and individual donors) should be used to determine the effect of hypothermia on the major drug uptake transporters
[OATP1B1/3, sodium-taurocholate cotransporting polypeptide (NTCP), organic cation transporter (OCT)1, organic anion transporter (OAT)2] and the sinusoidal
efflux transporter MRP3 (multidrug resistance-associated protein 3);
iii. Sandwich-cultured human hepatocytes (from at least 3 individual donors) and membrane vesicles to determine the effect of hypothermia on activity of key
canalicular [MultiDrug Resistance protein (MDR)-1, Multidrug Resistance-associated Protein (MRP)-2, Breast Cancer Resistance Protein (BCRP)] efflux
transporters;
iv. Similar in vitro experiments can be designed in at least 2 batches of minipig hepatocytes. Experiments with animal hepatocytes support unique insights into in
vitro in vivo extrapolation (IVIVE) provided corresponding in vivo studies in the same species are also conducted.
Study design and model compounds
• To allow distinction between effects on protein stability versus catalytic activity, incubations with the in vitro model systems should be conducted either during
hypothermia, or immediately after an in vitro hypothermia episode (60 min). Multiple cycles of hypothermia and warming may also be considered in an attempt
to mimic the in vivo impact of hypothermia (for 72 h) and warming on DME and DT activity.
• Depending on the research question, a strategic selection of probe substrates should include:
• ...the hepatically metabolized model compounds of interest (e.g. midazolam, fentanyl, phenobarbital because of their clinical relevance in the neonatal
population);
• ...established compounds for in vitro DME and DT phenotyping, and;
• ...compounds used as in vivo biomarkers of specific DME and DT activity, thus enabling more straightforward data interpretation as a well as scaling
towards the in vivo context.
Current challenges
• Relatively high inter-donor and/or inter-occasion variability in the obtained in vitro data is to be expected. This may complicate the use of the data for a robust
PBPK model.
• Mitigation strategies include more emphasis on the use of pooled microsomes/hepatocytes as well as the use of in vitro model systems expressing single
heterologously expressed DME and DT.
• The relatively large number of conditions to be evaluated necessities a tiered approach, based on initial selections of DMET model systems and substrates.
Delayed effects of hypothermia on mRNA expression, protein abundance and activity of hepatic DME and DT
Model systems and selected DME and DT
• Sandwich-cultured human (and possibly animal) hepatocytes (from at least 3 individual donors) should be used to determine the delayed (>24 h after
hypothermia episode) effect of hypothermia (72 h) on the mRNA expression and protein abundance of key DME (CYP1A2, CYP2C9, CY3A4) and DT
(OATP1B1/3, MRP).
Study design and model compounds
• Sandwich-cultured hepatocytes offer the advantage that hepatocytes can be used in study designs covering more than 1 week.
• The activity assays described for studying immediate effects (see above) are also applicable in this model system.
Current challenges
• Altered protein expression and activity in cultured hepatocytes will complicate extrapolation to in vivo effects. Analogous to interpretation and extrapolation of in
vitro induction response in cultured hepatocytes (Zhang et al., 2014), parallel evaluation of compounds exhibiting known in vivo impact of T° will be required.May 2020 | Volume 11 | Article 587
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models, including cats, dogs, guinea pigs, sheep, nonhuman
primates, pigs, rabbits, rats, and even bats (Painter, 1995).
Mice and rats have been shown to be useful models to study
the biochemical and pathological changes in the gray and white
matter of the brain following perinatal asphyxia, but they are not
considered to be appropriate models for studying damage to
peripheral organs such as the kidney (Larosa et al., 2017). Large
precocial animal models are much more useful in this regard as
they more closely mimic the human pathophysiological response
to PA, although they also have disadvantages when considering
their life span and consequently the life course of e.g. hypoxic–
ischemic encephalopathy.
Primates are definitely closer to humans on the phylogenetic
tree, but this does not always mean they are more suitable
asphyxia models. Body composition and hormonal changes
during pregnancy differ between man and nonhuman
primates. The nonhuman primate is much more advanced at
birth than the term human regarding its adaptive and
neuromotor maturity (Painter, 1995). Despite these limitations,
nonhuman primate studies have clearly shown that the
immature fetal brain has a greater degree of tolerance to an
asphyxial insult than the mature brain, and ischemia is also
required in addition to a reduced PaO2 to cause measurable brain
damage (Raju, 1992).
Due to the low cost and large size, the lamb has extensively
been studied under asphyxia conditions. It has been shown to be
a very valuable model to study cerebral blood flow and
metabolism (as reviewed by Raju, 1992). However, the
placental flow pattern and cerebral vascular anatomy are
distinctly different from those in man. Furthermore, it is
unclear whether the neuropathological changes in the lamb are
comparable to those in humans.
The neonatal piglet is also a good model to study the cerebral
blood flow and metabolism, and the model has also been well-
standardized in conventional pigs. It provides several advantages
such as similar development as that of a 36 to 38 weeks old
human fetus with comparable body systems, large body size at
birth (1.5–2 kg) that allows the instrumentation and monitoring
of the animal. Furthermore, the confounding variables of
hypoxia and hemodynamic derangements can be controlled
(Cheung et al., 2011). As the piglet asphyxia model is so well-
characterized, this also opens opportunities for pharmacologic
interventions and procedures applied in a clinical setting, such as
TH. For renal drug excretion, this has already been shown with
gentamicin. GFR in neonates with PA was about half the GFR of
neonates without PA, resulting in a decreased CL of gentamicin.
In addition, hypoxia–ischemia-induced renal impairment itself
also delays the excretion of gentamicin (Satas et al., 2000).
However, the impact of TH on hepatic metabolism of
administered drugs remains unclear and is difficult to study as
a separate covariate. As such, the piglet asphyxia model could
provide very useful information. The PK of dexmedetomidine
combined with TH has been studied in a piglet asphyxia model
by Ezzati et al. , (2014). These authors showed that
dexmedetomidine clearance was reduced almost 10-fold in theFrontiers in Pharmacology | www.frontiersin.org 13newborn piglet following hypoxic–ischemic brain injury and
subsequent TH compared with adult values. These high plasma
levels of the drug were associated with major cardiovascular
complications. However, the exact contribution of hypothermia
to the decreased clearance was not investigated in this study.
Furthermore, in view of new medicines under development
for the pediatric population, the conventional pig is not used.
The Göttingen Minipig is the most commonly used pig strain in
nonclinical drug development in Europe, as is the Beagle when
using the dog and the Sprague Dawley or Wistar when using the
rat. The Göttingen Minipig has several advantages compared to
conventional pigs, such as its small size, and they are easy to
handle, but the main advantage is that they are genetically
coherent. As such, they are well-characterized, and by using
the same strain, pharmaceutical companies can rely on historical
control data when interpreting findings in the safety studies. At
this point, drug metabolism has already been studied in
Göttingen Minipigs from fetal stage up to weaning, which
corresponds to approximately a 2-year old child, and in adults
(Van Peer et al., 2014; Van Peer et al., 2017). These studies
showed that the Göttingen Minipig has in general a similar
ontogeny pattern of CYP- and UGT-mediated metabolism
compared with neonates up to 2-year old children. This
strengthens the expectation that establishing an asphyxia
model with TH in this porcine strain could provide useful
information for the human condition.
In conclusion, animal models of PA may not entirely
represent the human situation, but it is clear that they have
advanced the understanding of this disease in man and still
provide new opportunities. In this regard, a neonatal Göttingen
Minipig asphyxia model with TH could provide very useful data
for drugs under development for pediatric use, but also for drugs
that are already currently used in neonatal intensive care units.Strategy for PBPK
Framework Evaluation
PBPK Hypothermia Framework Evaluation Using In
Vivo Animal and Human Data
As mentioned before, human (healthy) neonatal PBPK models
are already commercially available, and also for the adult
(Suenderhauf and Parrott, 2013) and juvenile Göttingen
Minipig (Van Peer et al., 2015) steps have been undertaken to
build PBPK models in this species. However, datasets on in vivo
drug disposition during asphyxia and/or hypothermia in the
neonatal Göttingen minipig and human neonatal cohorts need to
be built and can then be used to further construct and evaluate
the PBPK models. So far, only the combined impact of asphyxia
and hypothermia on disposition of drugs undergoing renal
elimination without metabolism has been well covered in man
and piglets. In contrast, in vivo disposition of drugs requiring
metabolism under hypothermia conditions is a knowledge gap.
As the potential role of hypothermia and asphyxia on drug
disposition in neonates cannot be investigated as separate
covariates in the clinical situation, a porcine neonatal in vivo
model can provide very useful data. More specifically, theMay 2020 | Volume 11 | Article 587
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situation by administering compounds, selected based on their
different physicochemical/PK characteristics and clinical
relevance, such as midazolam [CYP3A4; intermediate
extraction ratio (ER)], phenobarbital (CYP2C19; low ER),
topiramate (largely renally excreted unchanged), and fentanyl
(CYP3A4; high ER), in asphyxiated neonatal Göttingen minipigs
during TH. A second group contains asphyxiated neonatal
piglets under normal body-temperature, whereas a third group
contains nonasphyxiated neonatal piglets during hypothermia.
Controls, i.e. nonasphyxiated, normothermic piglets, also need to
be included. For human neonates with PA combined with TH
who often receive multiple drugs, available published datasets on
human in vivo observations of drug disposition can be used to
evaluate and further improve the PBPK hypothermia framework.
PBPK Software Qualification
According to the EMA guideline (EMA/CHMP/458101/2016—
effective mid 2019) on the reporting of PBPK modeling and
simulation, PBPK modeling efforts supporting regulatory
submissions require qualification of the software platform for
the intended use. The guideline lists expectations on how to
qualify such a software platform. In addition, demonstration of
predictive performance of PBPK models is considered an
essential part of PBPK M&S reports. It goes without saying that
such recommendations are also highly relevant in the context of
the development of a PBPK platform for dose prediction in
neonates under TH. Importantly, the guideline specifies that
PBPK models designed to predict pediatric drug dosing are
considered to be high (regulatory) impact applications.
Apart from model verification in terms of mathematical
structure, especially the availability of clinical reference, data is
crucial to support platform qualification. The guideline states
that several compounds with comparable ADME characteristics
should be included in a qualification ‘package'. It is not
surprising that inclusion of a higher number of ‘qualification
compounds' will generally lead to higher confidence in the PBPK
platform. The selection of such compounds will depend on the
availability of in vitro and in vivo data, as well as on the
contribution to the data set in terms of diversity of PK and
physicochemical characteristics. For the hypothermia PBPK
models, we provided model compound suggestions in the
section PBPK Hypothermia Framework Evaluation Using In
Vivo Animal and Human Data.
As already mentioned, this guideline also provides a
framework for evaluation of the predictive performance of the
drug-specific PBPK models. This essentially implies testing the
performance of the model under numerous different conditions
such as for example: (i) different populations; (ii) single versus
multiple dosing; (iii) dose-dependency (or lack thereof); (iv)
different dosage forms and/or routes of administration; (v)
supportive evidence from a corresponding nonclinical PBPK
model. It is noted that simulations should include a sufficiently
large number of subjects, which may help to predict population
variability of the outcomes.
Last but not least, developed PBPK models should be
subjected to sensitivity analyses, providing insight into theFrontiers in Pharmacology | www.frontiersin.org 14impact of imprecision in input variables (e.g. Log P, intrinsic
hepatic clearance) on predicted drug exposure. Plausibility
regarding the underlying drug disposition mechanisms can
provide guidance regarding the relevance to analyze the
sensitivity towards particular input variables.DISCUSSION
PBPK modeling and simulation can provide a link in translating
in vitro observations to real in vivo impact. It supports the
decision making about the need and priority of clinical trials,
but also for drug dose selection for a special patient population.
The strategy for the development and evaluation of a neonatal
hypothermia PBPK model, provided in this review, can be used
for personalized drug therapy and drug development. In the next
step, we aim to illustrate how this strategy can contribute to
achieve model-informed precision dosing in neonates with PA
undergoing TH.Case Example With Midazolam as
Model Drug
To provide an initial illustration regarding the potential
feasibility (and limitations) of PBPK modeling to predict the
impact of TH on PK, midazolam was chosen as a model drug
based on: (i) the availability of a significant amount of clinical PK
data, also in neonates; (ii) its PK profile, in view of the fact that it
is an intermediate ER drug. The latter implies that changes either
in hepatic blood flow or changes in intrinsic hepatic CL may
affect its PK behavior.
The clinical data on midazolam PK in 19 neonates on extra-
corporeal membrane oxygenation as published by Mulla et al.
(Mulla et al., 2003) were used as reference in vivo data because:
(i) newly generated simulations following iv infusion can be
directly compared to simulations published as part of the Mulla
study; (ii) ECMO-independent reference values for both CL and
Vd at steady state had been published; (iii) demographics of the
population including body weight (BW, mean 3.4 kg)
are available.
The PBPK models described below were all developed in
Simcyp v.18 (Certara) using the default physiochemical
parameters for midazolam and the default pediatric
population, selecting an age range of 0–28 days (neonates).
Initial model development included selection of the ‘full
PBPK'-mode, using a modified scalar on the tissue/plasma
partition coefficient (Kp) values in order to satisfy the Vd of
0.82 L/kg as reported by Mulla et al. However, as opposed to the
simulation published by Mulla et al. and for reasons of simplicity,
no loading dose was administered, but the same maintenance
dose level of 0.05 mg/h/kg BW was given for 72 h (total 3.6 mg/
kg), which is the typical duration of the TH. Figure 4 illustrates
the median ( ± 90% CI) predicted systemic concentration time
profile for midazolam in a virtual population of 19 ‘Simcyp
neonates' (mean BW 3.9 kg). The steady-state concentration
(Css)of 0.48 μg/ml is about 20% lower than the Css published by
Mulla et al. (~0.6 ~μ/ml). However, comparison of anMay 2020 | Volume 11 | Article 587
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of 3.4 kg (corresponding to the median BW in Mulla et al.),
reveals a Css of 0.74 μg/ml, providing confidence in the predictive
performance of the model, even though there appears to be a
significant impact of BW on hepatic CL. One can expect that
careful matching of virtual patients with the patients in the
reference study will further improve the predictive performance.
With this ‘basic' neonatal PBPK model for iv midazolam,
several sensitivity analyses were conducted to evaluate the
possible impact of TH on midazolam PK. Anticipated
temperature-induced alterations were explored for the
following parameters: (i) intrinsic hepatic formation CL for 1-Frontiers in Pharmacology | www.frontiersin.org 15OH-midazolam (CYP3A4) (Figure 5); (ii) 20% reduction in
cardiac output (CO); (iii) changes in blood/plasma ratio (B/P
ratio) and/or unbound fraction in plasma (fu_plasma) (Figure
6). As shown in Figures 5 and 6, realistic changes in Michaelis–
Menten constant (Km) and/or maximum reaction rate (Vmax) for
the 1-OH midazolam formation and in fu_plasma (rather than
B/P ratio) appeared to have a potentially clinically significant
impact on in vivo (hepatic) CL of midazolam. On the other hand,
a 20% reduction in CO did not have a substantial impact on the
predicted CL (data not shown). Also, the influence of changes in
renal midazolam CL were evaluated but no effects were seen,
more than likely due to the limited contribution of renal CL toFIGURE 4 | Median ( ± 90% CI) predicted systemic concentrations (Csys) of
midazolam following intravenous infusion at 0.05 mg/h/kg in 19 normothermic
neonates (mean body weight 3.91 ± 0.86 kg) for 72 h (total dose 3.6 mg/kg).
The solid line and the dashed lines represent the median and 5/95%
percentiles. The median concentration at steady state was 0.48 μg/ml.FIGURE 5 | Output of a sensitivity analysis for midazolam clearance (CL) in
neonates, illustrating the model-predicted impact of changes in Michaelis–
Menten constant (Km) and/or maximum reaction rate (Vmax) describing the
intrinsic formation CL of 1-OH midazolam by CYP3A4. The ‘dashed' circle
represents the Vmax/Km values at normothermia, while the yellow arrow
indicates a plausible change in Vmax (rather than Km) under conditions of
hypothermia.FIGURE 6 | Output of a sensitivity analysis for midazolam clearance (CL) in
neonates, illustrating the model-predicted impact of changes in unbound
fraction in plasma (fu_plasma) assuming a fixed blood/plasma ratio (B/P ratio)
of 0.55. A sensitivity analysis for the B/P ratio between 0.55 and 1.2 did not
reveal any significant changes in hepatic CL. During normothermia, the
reported fu value is 0.04.FIGURE 7 | Simulated midazolam median systemic plasma concentrations
(Csys) in neonates (n = 19; 0.05 mg/h/kg for 72 h; total dose 3.6 mg/kg)
under normothermic (green line) versus hypothermic (red line) conditions.
Therapeutic hypothermia (TH) was assumed to induce a 20% change in each
of the following parameters: cardiac output (decreased), unbound fraction (fu,
increased), blood/plasma ratio (B/P ratio, decreased) and 1-OH-midazolam
formation intrinsic clearance (CL, decreased). Dashed lines represent the 90%
CI for the hypothermic condition. Css: steady state concentration.May 2020 | Volume 11 | Article 587
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scenario, a hypothetical impact (i.e. 20%) of reduced temperature
on a combination of multiple parameters (CLint, CO, B/P ratio
and fu_plasma) was subsequently simulated (see Figure 7). A
23% increase in the median Css of midazolam was predicted
based on these assumed changes in parameters under TH. This
also implies a 20% decreased CL as Css solely depends on the
infusion rate and CL.
While additional in vitro data on intrinsic metabolism as well
as in vivo physiological data (including the impact of moderate
hypothermia) are needed, this initial set of simulations suggests
the utility of PBPK modeling to interrogate the impact of TH
regimens in neonates on PK. Clearly the predictive performance
of such models will highly depend on the scope and richness of
available input data. For instance, Empey et al. (Empey et al.,
2012) have previously shown that primarily metabolic capacity
(rather than enzyme affinity) affected systemic clearances of
fentanyl and midazolam. This finding primarily guides towards
evaluating temperature-dependent changes in Vmax (but with
constant Km) on simulated midazolam levels in human neonates
(see Figure 5).
These simulations are clinically relevant since they improve our
understanding of compound-specific disposition in a well-defined
pathophysiological condition and can be used to derive model-
informed precision dosing. Beyond the compound-specific
knowledge, these data are useful to further explore the impact of
other nonmaturational factors e.g. drug–drug interactions
(Allegaert et al., 2019). Based on in vivo observations, co-
administration of phenobarbital, a CYP3A inducer, will for
example increase midazolam CL in neonates treated with TH
with a factor 2.3 (95% CI 1.9–2.9) (Favie et al., 2019). This
knowledge allows for continuously refining available PBPKmodels.Reflections and Future Directions of
Temperature-Driven PBPK Models
Below, some additional reflections on the need, applicability, and
future directions of a PBPK hypothermia framework are made.
At present, TH has an effect size of 15% in the Western world.
However, in low- and middle-income countries where low-cost
hypothermia techniques are applied, no significant reduction in
neonatal mortality is documented (Pauliah et al., 2013; Albrecht
et al., 2019). Preventive measures to limit oxidative stress-related
brain injury in neonates with PA is especially important in low-
income countries since poor prenatal care and limited access to
health care contribute to neonatal morbidity and mortality. Early
obstetrical interventions as well as tailoring neuroprotective
strategies to settings limited to resources and technology are
needed (Solevag et al., 2019). Adequate randomized controlled
trials in this setting are challenging but needed before TH can be
offered as standard of care. Albrecht et al. also add that
alternative rescue treatments, including neuroprotective
pharmacotherapy, need to be cheap and easy to administer. In
addition, therapy needs to remain stable and not affected by
‘high' environmental temperature. On the one hand, this nicely
fits in the ‘asphyxia' part of our PBPK framework. On the otherFrontiers in Pharmacology | www.frontiersin.org 16hand, this also illustrates the broader need for temperature-
driven (high as well as low temperature) PBPK models.
The PBPK framework presented in this review is beneficial for
both academic and industry-driven research since new data
generation may facilitate development of temperature-driven
PBPK models for other populations or for other indications. As
highlighted by Gancia and Pomero, hypothermia is a promising
future therapy for acute ischemic stroke and improves survival
and outcome in adults with cardiac arrest. Consequently, further
research on other cooling modalities (timing, duration) and
indications (e.g. preterms, perinatal ischemic stroke,
postresuscitation, necrotising enterocolitis) in neonates and also
in other patient populations is suggested (Gancia and Pomero,
2011). Within the neonatal population, at present only neonates
with GA of at least 36 weeks receive TH. Nevertheless, also
preterm infants can present with HIE, but the symptoms and
pathology are different, including subcortical gray matter injury
combined with white matter damage. Studies in preterm fetal
sheep indicate that moderate cerebral hypothermia can reduce
both white and gray matter injury. Clinical reports on preterms
receiving hypothermia provide concerns about adverse effects,
morbidity, and mortality (Rao et al., 2017; Herrera et al., 2018).
Due to these concerns, it is suggested to first investigate TH in
systematic trials in late preterms (GA 31–36 weeks) with a clinical
picture in line with term cases suffering from HIE (Gunn and
Bennet, 2008). A randomized controlled trial including preterms
(GA 33–35 weeks) with moderate to severe encephalopathy,
investigating TH, is ongoing (Clinicaltrials.gov NCT01793129).
For preterm neonates with necrotizing enterocolitis with multiple
organ dysfunction syndrome, Hall et al. reported that mild
hypothermia for 48 h was feasible and safe. Additional study on
the efficacy of hypothermia for this special subpopulation is
certainly needed (Hall et al., 2010). When hypothermia PBPK
models would be applied for dose selection in these
subpopulations or new indications, the models should be
completed with system ontogeny data and covariates of the
respective population and/or disease condition. In general,
controlled temperature in clinical care becomes more popular,
but the impact on drug disposition often remains underexplored.
Within adult medicine, hyperthermic intraperitoneal
chemotherapy (HIPEC, optimal temperature range 41–43°C) is
used in oncology treatment (Kusamura et al., 2008). Surgery (to
eliminate all macroscopic disease) and HIPEC (to target residual
microscopic disease) combined have been recognized as therapy
of a subgroup of patients with e.g. peritoneal carcinomatosis.
However, different regimens of intraperitoneal chemotherapy
exist, and standardization in methodology for administration of
this therapy is lacking (Valle et al., 2016). PBPKmodels might also
be helpful to gain insight in drug disposition in these indications.FUTURE DIRECTIONS AND CONCLUSION
We recommend sharing the data (PK, systems ontogeny) and
models in open source platforms in order to make progress in the
field of thermo-pharmacology and to support the developmentMay 2020 | Volume 11 | Article 587
Smits et al. Neonatal Hypothermia PBPK Frameworkof temperature-driven PBPK models. This allows research
collaborations, not only for PBPK model development, but also
for validation efforts. Finally, besides PK, also research on PD
during hypothermia is needed. When drug exposure can be
predicted, the concentration–effect relationship needs further
attention. Also, for PD targets, (e.g. receptor expression and
activity), maturational as well as nonmaturational covariates
need to be taken into account, explaining variability in efficacy
of pharmacotherapy between and within patients. Study of PD in
neonates is challenging due to the lack of reference values (e.g.
biomarkers, vital parameters like blood pressure) and consensus
on definitions. Development of adequate nonclinical models to
investigate neonatal PD during PA and TH is of relevance.
In conclusion, this review summarized current evidence on the
impact of PA and TH on neonatal drug disposition and also
identified several knowledge gaps in this field. In order to enable
precision dosing during PA and TH, we proposed the development
of a robust PBPK framework by using a multidisciplinary,
translational approach. The applicability of the proposed
workflow and the challenges in the development of such a PBPKFrontiers in Pharmacology | www.frontiersin.org 17framework were illustrated for midazolam as a model drug.
However, this PBPK framework is clinically relevant in the broad
field of thermo-pharmacology, and recommendations for future
directions were provided.AUTHOR CONTRIBUTIONS
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